<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452140</url>
  </required_header>
  <id_info>
    <org_study_id>IV-ERT-BC-03</org_study_id>
    <secondary_id>EudraT number: 2006-005017-36</secondary_id>
    <nct_id>NCT00452140</nct_id>
  </id_info>
  <brief_title>Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment</brief_title>
  <official_title>Phase II Study for Repeated Dosing of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients With HER-2/Neu 1+ or 2+/FISH Negative Expressing Advanced or Metastatic Breast Cancer (Stage IIIb/IV) Progressing After Endocrine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to demonstrate clinical efficacy of the investigational&#xD;
      trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or&#xD;
      2+ (FISH-) expressing advanced or metastatic breast cancer (stage III b/IV) which has&#xD;
      progressed after endocrine therapy.&#xD;
&#xD;
      Ertumaxomab is a trifunctional bispecific antibody targeting Her-2/neu and CD3 on T cells.&#xD;
      Trifunctional antibodies represent a new concept for targeted anticancer therapy. This new&#xD;
      antibody class has the capability to redirect T cells and accessory cells (e.g. macrophages,&#xD;
      dendritic cells [DCs] and natural killer [NK] cells) to the tumor site. According to&#xD;
      preclinical data, trifunctional antibodies activate these immune cells, which can trigger a&#xD;
      complex anti-tumor immune response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, non-randomized, uncontrolled, one-stage, phase II study evaluating the&#xD;
      efficacy and safety of the investigational trifunctional bispecific antibody ertumaxomab&#xD;
      (anti-Her-2/neu x anti-CD3) for the treatment of hormone therapy refractory advanced or&#xD;
      metastatic breast cancer tumours (stage IIIb or IV) which are known to express HER-2/neu (1+&#xD;
      or 2+/FISH negative).Ertumaxomab will be administered at 7 day intervals by constant rate 3&#xD;
      hour intravenous (i.v.) infusions according to the following sequential dose schedule: 10 µg&#xD;
      (day 0) and thereafter 100 µg flat doses once every 7 days (± 1 day) for a maximum of up to&#xD;
      12 weeks or until disease progression or any other unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    company focus on other projects&#xD;
  </why_stopped>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficacy measured by objective response rate (best response during the course of the study)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of human anti-murine antibodies after ertumaxomab infusion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ertumaxomab</intervention_name>
    <description>10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  Women ≥ 18 years, negative pregnancy test at screening life expectancy of at least 6&#xD;
             months&#xD;
&#xD;
          -  Locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma&#xD;
             of the breast&#xD;
&#xD;
          -  Measurable disease, defined as at least one lesion that is measurable in one dimension&#xD;
             (RECIST)&#xD;
&#xD;
          -  HER-2/neu expression 1+ or 2+ / FISH negative&#xD;
&#xD;
          -  Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive&#xD;
&#xD;
          -  Prior adequate endocrine therapy for advanced or metastatic disease&#xD;
&#xD;
          -  Disease progression during or after endocrine therapy&#xD;
&#xD;
          -  No prior treatment with mouse or rat antibodies&#xD;
&#xD;
          -  ECOG performance score of ≤ 1&#xD;
&#xD;
          -  Adequate hematological, liver and kidney function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
&#xD;
          -  Known HIV infection or Presence of autoimmune disease or other Concurrent&#xD;
             non-malignant co-morbidities that are uncontrolled&#xD;
&#xD;
          -  History or symptoms indicative of brain or CNS metastases&#xD;
&#xD;
          -  Prior diagnosis of any malignancy not cured by surgery alone less than 5 years before&#xD;
             study entry (except in situ carcinoma of the cervix or adequately treated basal cell&#xD;
             carcinoma of the skin)&#xD;
&#xD;
          -  Documented acute or chronic infection requiring antibiotic treatment&#xD;
&#xD;
          -  Any concurrent chemo-, hormonal, immuno- or corticoid therapy&#xD;
&#xD;
          -  Any prior chemotherapy for advanced or metastatic disease&#xD;
&#xD;
          -  Any concurrent investigational treatment for advanced or metastatic disease&#xD;
&#xD;
          -  History of relevant cardiovascular disease as follows:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) below the institution's lower limit of&#xD;
                  normal, based on echocardiography (ECG) at rest&#xD;
&#xD;
               -  Uncontrolled or symptomatic congestive heart failure (New York Heart Association&#xD;
                  (NYHA) &gt; 2&#xD;
&#xD;
               -  Uncontrolled or symptomatic arrhythmia and/or angina pectoris&#xD;
&#xD;
               -  Myocardial infarction during the last 2 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Baselga / Javier Cortes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron, Barcelona, Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Study site</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Study site</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Study sites</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Study site</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M. Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006 May 15;12(10):3085-91.</citation>
    <PMID>16707606</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000 Jul;83(2):261-6.</citation>
    <PMID>10901380</PMID>
  </reference>
  <reference>
    <citation>Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999 Aug 1;163(3):1246-52.</citation>
    <PMID>10415020</PMID>
  </reference>
  <reference>
    <citation>Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001 Oct 15;98(8):2526-34.</citation>
    <PMID>11588051</PMID>
  </reference>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <last_update_submitted>May 18, 2009</last_update_submitted>
  <last_update_submitted_qc>May 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fresenius Biotech GmbH</name_title>
    <organization>Fresenius Biotech GmbH</organization>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>investigational drug</keyword>
  <keyword>drug therapy</keyword>
  <keyword>Antineoplastic Protocols</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Advanced breast cancer</keyword>
  <keyword>Stage III to IV breast cancer</keyword>
  <keyword>Hormonal therapy refractory</keyword>
  <keyword>Failure of hormonal therapy</keyword>
  <keyword>Her-2/neu expressing breast cancer</keyword>
  <keyword>Her-2/neu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

